

## Product Datasheet

### Tropifexor (orb1226396)

<b>Catalog Number</b>	orb1226396
<b>Category</b>	Small Molecules
<b>Description</b>	<p>Tropifexor (LJN-452, LJN452) is a novel highly potent, selective, orally active FXR full agonist with EC<sub>50</sub> of 0.26 nM; shows no significant off-target activity (&gt;10,000-fold selectivity for FXR) in a panel of targets, including TGR5 (&gt;10 μM); demonstrates in vivo activity in rodent PD models, and shows potential for treatment of cholestatic liver diseases and NASH. Steatohepatitis, Phase 2 Clinical (In Vitro): Tropifexor (compound 1) is a novel and highly potent agonist of FXR with an EC<sub>50</sub> of 0.2 nM. Robust induction of both BSEP and SHP genes is observed in primary cells by Tropifexor in a concentration-dependent manner. BSEP induction above vehicle (DMSO) control is observed at concentrations as low as 1 nM, while strong induction of SHP (15-fold above vehicle) is observed at 10 nM and modest induction of SHP at 1 nM (3-fold).</p> <p>(In Vivo): Tropifexor (compound 1) demonstrates highly potent induction of SHP and FGF15 in the ileum as doses as low as 0.1 mg/kg. In the liver, robust induction of SHP is observed at 0.01 mg/kg of Tropifexor with maximal levels of gene induction achieved at 0.3 mg/kg. Expression of CYP8B1 mRNA following 14 day treatment with Tropifexor is already apparent at the lowest dose (0.003 mg/kg), and CYP8B1 gene expression is fully repressed at doses above 0.03 mg/kg. Treatment of rats with Tropifexor exhibits a clear dose-dependent increase in plasma FGF15 protein, with maximal levels of FGF15 detected at 7 h postdose. Treatment with Tropifexor for 14 days produces a robust dose-dependent reduction in serum triglycerides and reaches a maximal response with a 0.3 mg/kg dose, resulting in a decrease of triglyceride levels to approximately 79% below the vehicle control group.</p>
<b>Target</b>	FXR
<b>Purity</b>	>98% (HPLC)
<b>MW</b>	603.589
<b>Target Areas</b>	FXR

#### Biorbyt Ltd.

7 Signet Court, Swann Road  
Cambridge  
CB5 8LA  
United Kingdom

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)  
Phone: +44 (0)1223 859353 | Fax: +1 (415) 651-8558

#### Biorbyt LLC

68 TW Alexander Drive  
Research Triangle Park  
Durham  
NC 27713  
United States

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)  
Phone: +1 (415) 906-5211 | Fax: +1 (415) 651-8558

<b>Solubility (25°C)</b>	10 mM in DMSO
<b>CAS Number</b>	1383816-29-2
<b>Formula</b>	C <sub>29</sub> H <sub>25</sub> F <sub>4</sub> N <sub>3</sub> O <sub>5</sub> S
<b>SMILES</b>	<chem>O=C(C1=CC(F)=C2N=C(N3[C@@]4([H])C[C@H](OCC5=C(C6CC6)ON=C5C7=CC=CC=C7OC(F)(F)F)[C@]3([H])CC4)SC2=C1)O</chem>
<b>Chemical Name</b>	2-[(1R,3r,5S)-3-(5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid
<b>Storage</b>	Storage temperature: -20°C. Stability: ≥ 2 years
<b>Note</b>	For research use only
<b>Expiration Date</b>	12 months from date of receipt.

**Biorbyt Ltd.**

7 Signet Court, Swann Road  
Cambridge  
CB5 8LA  
United Kingdom

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)

Phone: [+44 \(0\)1223 859353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)651-8558)

**Biorbyt LLC**

68 TW Alexander Drive  
Research Triangle Park  
Durham  
NC 27713  
United States

Email: [info@biorbyt.com](mailto:info@biorbyt.com), [support@biorbyt.com](mailto:support@biorbyt.com)

Phone: [+1 \(415\) 906-5211](tel:+1(415)906-5211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)651-8558)